MabVax Therapeutics Holdings, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Its lead cancer vaccines targeting recurrent sarcoma and ovarian cancer are in proof of concept Phase II multi-center clinical trials. The company's product candidates include MVT-5873, a therapeutic antibody that is in Phase I clinical trial for patients with advanced or metastatic adenocarcinoma of the pancreas (PDAC) and other CA19-9 positive malignancies; and MVT-2163, an immuno-positron emission tomography (PET) imaging agent, which is in Phase I clinical trial designed to evaluate a next generation diagnostic PET imaging agent in patients with PDAC or other CA19-9 positive malignancies. Its product candidates also comprise MVT-1075, a radioimmunotherapy agent that combines the company's HuMab-5B1 antibody with the radiopharmaceutical (177) Lutetium to treat pancreatic cancer. The company has various research agreements and collaborations with Memorial Sloan Kettering Cancer Center; a licensing agreement with Life Technologies Corporation; a research collaboration agreement with Rockefeller University's Laboratory of Molecular Genetics and Immunology; and a development and manufacturing services agreement with Patheon. MabVax Therapeutics Holdings, Inc. was founded in 2006 and is based in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-259-9405
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Mabvax Therapeutics (NASDAQ:MBVX) Frequently Asked Questions
What is Mabvax Therapeutics' stock symbol?
Mabvax Therapeutics trades on the NASDAQ under the ticker symbol "MBVX."
When did Mabvax Therapeutics' stock split? How did Mabvax Therapeutics' stock split work?
Mabvax Therapeutics's stock reverse split on Friday, February 16th 2018. The 1-3 reverse split was announced on Thursday, February 15th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 15th 2018. An investor that had 100 shares of Mabvax Therapeutics stock prior to the reverse split would have 33 shares after the split.
How were Mabvax Therapeutics' earnings last quarter?
Mabvax Therapeutics Holdings Inc (NASDAQ:MBVX) announced its earnings results on Tuesday, November, 7th. The company reported ($1.62) earnings per share (EPS) for the quarter. View Mabvax Therapeutics' Earnings History.
Has Mabvax Therapeutics been receiving favorable news coverage?
Media stories about MBVX stock have been trending somewhat positive on Saturday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mabvax Therapeutics earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Mabvax Therapeutics.
Who are some of Mabvax Therapeutics' key competitors?
Some companies that are related to Mabvax Therapeutics include Orexigen Therapeutics (OREXQ), Inspyr Therapeutics (NSPX), Immune Therapeutics (IMUN), Advanz Pharma (CXRXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), American Oriental Bioengineering (AOBI), Aoxing Pharmaceutical (AOXG), Bohai Pharmaceuticals Group (BOPH), Eleven Biotherapeutics (EBIO), Epirus Biopharmaceuticals (EPRSQ), ERBA Diagnostics (ERBA), FutureWorld (FWDG), GlobeImmune (GBIM) and Mereo BioPharma Group (MREO).
What other stocks do shareholders of Mabvax Therapeutics own?
Who are Mabvax Therapeutics' key executives?
Mabvax Therapeutics' management team includes the folowing people:
- Mr. John David Hansen, Chairman, Pres & CEO (Age 67)
- Prof. Philip O. Livingston, Co-Founder, Chief Science Officer & Director (Age 75)
- Mr. Gregory P. Hanson C.M.A., M.B.A., MBA, CMA, Chief Financial Officer (Age 71)
- Dr. Paul W. Maffuid, Exec. VP of R&D (Age 63)
- Dr. Paul F. Resnick, VP & Chief Bus. Officer (Age 61)
What is Mabvax Therapeutics' stock price today?
One share of MBVX stock can currently be purchased for approximately $0.01.
How big of a company is Mabvax Therapeutics?
What is Mabvax Therapeutics' official website?
How can I contact Mabvax Therapeutics?
Mabvax Therapeutics' mailing address is 11535 SORRENTO VALLEY ROAD SUITE 400, SAN DIEGO CA, 92121. The company can be reached via phone at 858-259-9405 or via email at [email protected]
MarketBeat Community Rating for Mabvax Therapeutics (NASDAQ MBVX)
MarketBeat's community ratings are surveys of what our community members think about Mabvax Therapeutics and other stocks. Vote "Outperform" if you believe MBVX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBVX will underperform the S&P 500 over the long term. You may vote once every thirty days.
